The extracellular regulation of growth factor action.

The concept that growth factors act as autocrine and paracrine regulators of cell growth and differentiation was introduced over a decade ago (Sporn and Todaro, 1980). Since then significant advances have been made in understanding the regulation of growth factor expression and interaction with high affinity plasma membrane receptors. More recently, structural analysis and in vitro experiments suggest that regulatory mechanisms other than growth factor expression and receptor binding dominate growth factor action. These data demonstrate that most growth factors do not simply diffuse passively from the site of their release to interact with the nearest cell surface receptor. Rather, many of these proteins contain structural features that foster their interaction with other molecules within the extracellular environment. These interactions confine the action of the growth factor to an appropriate place and time. Thus, the specificity of growth factor signaling is derived not only from its binding to cell surface receptors but also through critical interactions with other components of the extracellular environment. In this review we will describe recently appreciated mechanisms involved in the nonreceptor mediated extracellular regulation of growth factor activity.

[1]  R. Ross,et al.  Compartmentalization of PDGF on extracellular binding sites dependent on exon-6-encoded sequences , 1992, The Journal of cell biology.

[2]  J. Gabrilove,et al.  Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan , 1991, The Journal of cell biology.

[3]  C. Brannan,et al.  Requirement for mast cell growth factor for primordial germ cell survival in culture , 1991, Nature.

[4]  S. Aaronson,et al.  A novel mechanism regulating growth factor association with the cell surface: identification of a PDGF retention domain. , 1991, Genes & development.

[5]  D. Williams,et al.  Steel-Dickie mutation encodes a c-kit ligand lacking transmembrane and cytoplasmic domains. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Sporn,et al.  Cytokines in context , 1991, The Journal of cell biology.

[7]  Y. Kita,et al.  Role of glycosaminoglycans in the regulation of T cell proliferation induced by thymic stroma-derived T cell growth factor. , 1991, Journal of Immunology.

[8]  G. Giménez-Gallego,et al.  Conversion of cysteine to serine residues alters the activity, stability, and heparin dependence of acidic fibroblast growth factor. , 1991, The Journal of biological chemistry.

[9]  P. Leder,et al.  Transmembrane form of the kit ligand growth factor is determined by alternative splicing and is missing in the SId mutant , 1991, Cell.

[10]  Erkki Ruoslahti,et al.  Proteoglycans as modulators of growth factor activities , 1991, Cell.

[11]  J. Massagué,et al.  Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Klagsbrun,et al.  A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF , 1991, Science.

[13]  Jeffrey D. Esko,et al.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor , 1991, Cell.

[14]  D. Rifkin,et al.  Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Levinson,et al.  Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1 , 1990, The Journal of experimental medicine.

[16]  L. Gooding,et al.  A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact , 1990, Cell.

[17]  G. Duff,et al.  A soluble form of the interleukin‐1 receptor produced by a human B cell line , 1990, FEBS letters.

[18]  C. March,et al.  Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms , 1990, Cell.

[19]  M. Feldmann,et al.  Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Brody,et al.  PDGF‐stimulated fibroblast proliferation is enhanced synergistically by receptor‐recognized α2‐Macroglobulin , 1990, Journal of cellular physiology.

[21]  C. W. Rettenmier,et al.  Direct stimulation of cells expressing receptors for macrophage colony-stimulating factor (CSF-1) by a plasma membrane-bound precursor of human CSF-1. , 1990, Blood.

[22]  Austin G Smith,et al.  Differentiation inhibiting activity is produced in matrix-associated and diffusible forms that are generated by alternate promoter usage , 1990, Cell.

[23]  D. Johnson,et al.  Diverse forms of a receptor for acidic and basic fibroblast growth factors , 1990, Molecular and cellular biology.

[24]  A. Paterson,et al.  Transforming growth factor alpha in arterioles: cell surface processing of its precursor by elastases , 1990, Molecular and cellular biology.

[25]  D. Rifkin,et al.  Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self- regulating system , 1990, The Journal of cell biology.

[26]  E. Ruoslahti,et al.  Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. , 1990, The Journal of clinical investigation.

[27]  L. Gentry,et al.  The pro domain of pre-pro-transforming growth factor beta 1 when independently expressed is a functional binding protein for the mature growth factor. , 1990, Biochemistry.

[28]  E. Ruoslahti,et al.  Negative regulation of transforming growth factor-β by the proteoglycan decorin , 1990, Nature.

[29]  B. Schryver,et al.  Secreted int-1 protein is associated with the cell surface. , 1990, Molecular and cellular biology.

[30]  C. Disteche,et al.  The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity , 1990, Molecular and cellular biology.

[31]  J. Massagué,et al.  Cell-cell adhesion mediated by binding of membrane-anchored transforming growth factor alpha to epidermal growth factor receptors promotes cell proliferation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Sporn,et al.  Differential inhibition of transforming growth factor beta 1 and beta 2 activity by alpha 2-macroglobulin. , 1990, The Journal of biological chemistry.

[33]  G. Wong,et al.  Molecular cloning and expression of a receptor for human tumor necrosis factor , 1990, Cell.

[34]  H. Moses,et al.  Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin , 1990, The Journal of cell biology.

[35]  T. Nakamura,et al.  Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[36]  C. Betsholtz,et al.  Analogous alternative splicing , 1990, Nature.

[37]  D. Rifkin,et al.  Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. , 1990 .

[38]  K. Miyazono,et al.  Latent form of transforming growth factor-beta 1 acts as a potent growth inhibitor on a human erythroleukemia cell line. , 1990, Biochemical and biophysical research communications.

[39]  E. Chambaz,et al.  Transforming growth factor-beta stimulates the expression of alpha 2-macroglobulin by cultured bovine adrenocortical cells. , 1990, The Journal of biological chemistry.

[40]  L. Bonewald,et al.  Characterization of the latent transforming growth factor ß complex in Bone , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[42]  D. Wallach,et al.  Soluble cytokine receptors are present in normal human urine , 1989, Journal of Experimental Medicine.

[43]  Alan I. Alpert,et al.  The murine interleukin-4 receptor: Molecular cloning and characterization of secreted and membrane bound forms , 1989, Cell.

[44]  D. Wallach,et al.  Soluble cytokine receptors are present in normal human urine , 1989, The Journal of experimental medicine.

[45]  D. Simon,et al.  cDNA sequence and chromosomal localization of the mouse parvalbumin gene, Pva. , 1989, Genetical research.

[46]  J. Downing,et al.  Ligand and protein kinase C downmodulate the colony-stimulating factor 1 receptor by independent mechanisms , 1989, Molecular and cellular biology.

[47]  D. Rifkin,et al.  Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture , 1989, The Journal of cell biology.

[48]  B. Mroczkowski,et al.  Recombinant human epidermal growth factor precursor is a glycosylated membrane protein with biological activity , 1989, Molecular and cellular biology.

[49]  F. Welt,et al.  Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2- macroglobulin inactive complex , 1989, The Journal of cell biology.

[50]  P. Jullien,et al.  Acidic cellular environments: Activation of latent tgf‐β and sensitization of cellular responses to tgf‐β and egf , 1989 .

[51]  D. Rifkin,et al.  Alpha 2-macroglobulin is a binding protein for basic fibroblast growth factor. , 1989, The Journal of biological chemistry.

[52]  L. Bonewald,et al.  Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. , 1989, Biochemical and biophysical research communications.

[53]  J. Massagué,et al.  The TGF-α precursor expressed on the cell surface binds to the EGF receptor on adjacent cells, leading to signal transduction , 1989, Cell.

[54]  J. Wagner,et al.  Heparin potentiates the action of acidic fibroblast growth factor by prolonging its biological half‐life , 1989, Journal of cellular physiology.

[55]  T. Hirano,et al.  Identification of alpha 2-macroglobulin as a carrier protein for IL-6. , 1989, Journal of immunology.

[56]  D. Rifkin,et al.  Interaction of heparin with human basic fibroblast growth factor: Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan , 1989, Journal of cellular physiology.

[57]  D. Rifkin,et al.  Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation , 1988, The Journal of cell biology.

[58]  H. Moses,et al.  Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium , 1988, The Journal of cell biology.

[59]  R. Friesel,et al.  Heparin protects heparin-binding growth factor-I from proteolytic inactivation in vitro. , 1988, Biochemical and biophysical research communications.

[60]  E. Appella,et al.  Structure and function of epidermal growth factor‐like regions in proteins , 1988, FEBS letters.

[61]  R Guillemin,et al.  Receptor- and heparin-binding domains of basic fibroblast growth factor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[62]  T. Dexter,et al.  Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis , 1988, Nature.

[63]  E Ruoslahti,et al.  New perspectives in cell adhesion: RGD and integrins. , 1987, Science.

[64]  M. O’Connor-McCourt,et al.  Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin. , 1987, The Journal of biological chemistry.

[65]  D. Moscatelli,et al.  High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells , 1987, Journal of cellular physiology.

[66]  R. Derynck,et al.  Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells , 1987, Cell.

[67]  D. Gospodarowicz,et al.  Heparin protects basic and acidic FGF from inactivation , 1986, Journal of cellular physiology.

[68]  M. Czech,et al.  Purification and amino-terminal sequence of an insulin-like growth factor-binding protein secreted by rat liver BRL-3A cells. , 1986, The Journal of biological chemistry.

[69]  E. Froesch,et al.  Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. , 1986, The Journal of clinical investigation.

[70]  Anita B. Roberts,et al.  Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells , 1985, Nature.

[71]  I. Kerr,et al.  Purification and characterization of vaccinia virus growth factor , 1985, Cell.

[72]  S. Aaronson,et al.  The v‐sis/PDGF‐2 transforming gene product localizes to cell membranes but is not a secretory protein. , 1985, The EMBO journal.

[73]  R. Nusse,et al.  Structure and nucleotide sequence of the putative mammary oncogene int-1; proviral insertions leave the protein-encoding domain intact , 1984, Cell.

[74]  E. Chen,et al.  Human transforming growth factor-α: Precursor structure and expression in E. coli , 1984, Cell.

[75]  F. Ito,et al.  Transmembrane delivery of polypeptide growth factors bypassing the intrinsic cell surface receptors: synthesis and biological activity of a conjugate of epidermal growth factor with alpha 2-macroglobulin. , 1984, Cell structure and function.

[76]  J. Spiess,et al.  Production of an epidermal growth factor receptor-related protein. , 1984, Science.

[77]  E. Levine,et al.  Human endothelial cells: use of heparin in cloning and long-term serial cultivation. , 1983, Science.

[78]  A. Ullrich,et al.  Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor , 1983, Nature.

[79]  D. Clemmons,et al.  Liberation of immunoreactive somatomedin-C from its binding proteins by proteolytic enzymes and heparin. , 1983, Journal of Clinical Endocrinology and Metabolism.

[80]  G. Smith,et al.  Inhibition of biological activity of multiplication-stimulating activity by binding to its carrier protein. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[81]  M. Sporn,et al.  Autocrine secretion and malignant transformation of cells. , 1980, The New England journal of medicine.

[82]  P. A. Peterson,et al.  Nerve growth factor binds to serum alpha-2-macroglobulin. , 1979, Biochemical and biophysical research communications.

[83]  S. W. Hall,et al.  An alpha 2-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-beta 1 in mice. , 1991, The Journal of clinical investigation.

[84]  M. Sporn,et al.  The Multifunctional Nature of Peptide Growth Factors , 1991 .

[85]  K. Miyazono,et al.  TGF-beta 1 binding protein: a component of the large latent complex of TGF-beta 1 with multiple repeat sequences. , 1990, Cell.

[86]  R. Hintz Role of growth-hormone and insulin-like growth-factor-binding proteins. , 1990, Hormone research.

[87]  M. Sporn,et al.  Sandwich Enzyme-Linked Immunosorbent Assays (Selisas) Quantitate and Distinguish Two Forms of Transforming Growth Factor-Beta (TGF-β1 and TGF-β2) in Complex Biological Fluids , 1989 .

[88]  P. Hauschka,et al.  Polypeptide growth factors in bone matrix. , 1988, Ciba Foundation symposium.

[89]  T. Deuel,et al.  Specific covalent binding of platelet-derived growth factor to human plasma alpha 2-macroglobulin. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[90]  E. Chen,et al.  Human transforming growth factor-alpha: precursor structure and expression in E. coli. , 1984, Cell.

[91]  E. Froesch,et al.  Demonstration of a specific serum carrier protein of nonsuppressible insulin-like activity in vivo. , 1977, The Journal of clinical endocrinology and metabolism.

[92]  S. Nissley,et al.  The serum half-life of somatomedin activity: evidence for growth hormone dependence. , 1976, Acta Endocrinologica.